

Figure S1: Follow-up duration following cladribine induction among different treatment subgroups. Data are shown Median \pm IQR; whiskers indicate 5% to 95%. IFN/GLAT: beta-interferon/glatiramer acetate. DMF: dimethyl fumarate; FTY: fingolimod; NTZ: natalizumab.




Figure S2: Efficacy outcomes of our cohort stratified according to the last previous DMT using the Kaplan-Meier method. Numbers at risk are displayed below the respective graphs. **A:** Proportion of patients without a clinical relapse over time. **B:** Proportion of patients without new or enlarging T2-hyperintense MRI lesions. DMF: dimethyl fumarate; FTY: fingolimod; NTZ: natalizumab. NEDA3: no evidence of disease activity-3.